Voyager Therapeutics presented positive safety data for its Alzheimer's gene therapy, VY1706, at a major conference. The treatment lowered tau protein by up to 75% in key brain areas and was well-tolerated in animal studies. The company has FDA clearance and plans to start testing in humans in the second half of 2026.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding VOYAGER THERAPEUTICS INC (VYGR)?

Major stakeholders currently include BlackRock, Inc. ($21.5M), Armistice Capital, LLC ($13.5M), Millennium Management LLC ($13.2M). Based on the latest 13F filings, there are a total of 135 tracked investment funds and institutions maintaining positions in VYGR.

What is the overall institutional sentiment toward VYGR recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $2.9M, driven by 69 managers accumulating shares while 55 reduced their exposure.

Which institutions have been selling or reducing their VYGR positions?

In the latest period, 38 funds trimmed their holdings, and 17 managers completely exited their positions. The aggregate reported sell value was $85.8M.

Are there any notable investors adding VYGR to their portfolios?

Yes, buying activity remains notable. 24 institutions opened new positions in {ticker}, and 45 existing holders added to their shares. The total reported buy value for the quarter amounted to $56.1M.